【醫(yī)學(xué)課件】ease研究ppt課件-wenkub
2022-11-03 06:49:16 本頁面
【正文】 2 . 81 . 31 . 6 0 . 8202468101214Reduction in Triglycerides p Presented at ACC Scientific Sessions 2021 EASE Trial ?A large proportion of patients in the trial had diabetes (%) and metabolic syndrome by NCEP ATP III criteria (60%). ?Baseline LDL levels were 129 mg/dl in the overall population, 123 mg/dl in the coronary heart disease (CHD) or CHD risk equivalent group, 147 mg/dl in the multiple risk factors group, and 167 mg/dl in the 2 risk factors group. ?The ezetimibe arm had a larger reduction in triglycerides and a larger increase in highdensity lipoprotein (HDL) levels. Ezetimibe Placebo mg/dl Increase in HighDensity Lipoprotein (HDL) p Ezetimibe Placebo . Clinical trial 7 1 . 0 %2 0 .
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1